REPLIGEN CORP Deferred Revenue, Revenue Recognized (Deprecated 2016-01-31)
REPLIGEN CORP (RGEN) reported Deferred Revenue, Revenue Recognized (Deprecated 2016-01-31) of $2.12 million for the 3-month period ending 2016-03-31, per its 10-Q filed 2016-05-05.
Discontinued › Income Statement › Other Income
us-gaap:DeferredRevenueRevenueRecognized · last filed 2016-05-05
- REPLIGEN CORP deferred revenue, revenue recognized (deprecated 2016-01-31) for the quarter ending 2016-03-31 was $2.12M, a 0.00% change year-over-year.
- REPLIGEN CORP deferred revenue, revenue recognized (deprecated 2016-01-31) for the quarter ending 2015-03-31 was $2.12M, a 0.00% change year-over-year.
- REPLIGEN CORP deferred revenue, revenue recognized (deprecated 2016-01-31) for the quarter ending 2014-03-31 was $2.12M.
- REPLIGEN CORP deferred revenue, revenue recognized (deprecated 2016-01-31) for fiscal 2015 was $2.12M, a 0.00% change from fiscal 2014.
- REPLIGEN CORP deferred revenue, revenue recognized (deprecated 2016-01-31) for fiscal 2014 was $2.12M.
| Period end | Deferred Revenue, Revenue Recognized (Deprecated 2016-01-31) 3 month | Deferred Revenue, Revenue Recognized (Deprecated 2016-01-31) 6 month | Deferred Revenue, Revenue Recognized (Deprecated 2016-01-31) 9 month | Deferred Revenue, Revenue Recognized (Deprecated 2016-01-31) 12 month |
|---|---|---|---|---|
| 2016-03-31 | $2.12M 10-Q · filed 2016-05-05 | |||
| 2015-12-31 | $2.12M 10-K · filed 2016-02-25 | |||
| 2015-09-30 | $2.12M 10-Q · filed 2015-11-05 | |||
| 2015-06-30 | $2.12M 10-Q · filed 2015-08-06 | |||
| 2015-03-31 | $2.12M 10-Q · filed 2015-05-08 | |||
| 2014-12-31 | $2.12M 10-K · filed 2015-03-17 | |||
| 2014-09-30 | $2.12M 10-Q · filed 2014-11-07 | |||
| 2014-06-30 | $2.12M 10-Q · filed 2014-08-11 | |||
| 2014-03-31 | $2.12M 10-Q · filed 2014-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |